Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16322486 | 1.00 | SMN1; SMN2 (0.70) | SMN1; SMN2HTTCYP3A4CYP2B6POLB | |
| SCHEMBL16324039 | 0.90 | SMN1; SMN2 (0.69) | SMN1; SMN2HTTCYP3A4CYP2B6TP53 | |
| SCHEMBL16324040 | 0.90 | SMN1; SMN2 (0.69) | SMN1; SMN2HTTCYP3A4CYP2B6TP53 | |
| SCHEMBL16325116 | 0.88 | SMN1; SMN2 (0.71) | SMN1; SMN2HTTCYP3A4CYP2B6POLB | |
| SCHEMBL16325115 | 0.88 | SMN1; SMN2 (0.71) | SMN1; SMN2HTTCYP3A4CYP2B6POLB | |
| SCHEMBL16321033 | 0.88 | HTT (0.54) | SMN1; SMN2HTTCYP3A4CYP2B6 | |
| SCHEMBL16321035 | 0.88 | HTT (0.54) | SMN1; SMN2HTTCYP3A4CYP2B6 | |
| SCHEMBL16321643 | 0.88 | SMN1; SMN2 (0.53) | SMN1; SMN2HTTCYP3A4CYP2B6TP53 | |
| SCHEMBL16321646 | 0.88 | SMN1; SMN2 (0.53) | SMN1; SMN2HTTCYP3A4CYP2B6TP53 | |
| SCHEMBL16320817 | 0.87 | HTT (0.53) | SMN1; SMN2HTTCYP3A4CYP2B6ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744664-A2 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | MyoKardia, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20240382486-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2024-11-21 | — | — | US | disclosed |
| US-RE50050-E1 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2023-06-01 | — | — | US | disclosed |
| US-20210346379-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20200297726-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2020-09-24 | — | — | US | disclosed |
| EP-3702352-A1 | PYRIMIDINEDIONE COMPOUND AGAINST CARDIAC CONDITIONS | Myokardia, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
| EP-3010910-B1 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | MYOKARDIA INC (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20180311242-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2018-11-01 | — | — | US | disclosed |
| US-20170281626-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-9585883-B2 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-3010910-A1 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | Myokardia, Inc. (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20160030428-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2016-02-04 | — | — | US | disclosed |
| US-9181200-B2 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2014-12-25 | — | — | US | disclosed |
| WO-2014205223-A1 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | MyoKardia, Inc. (US) | 2014-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346379-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885 |
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885 |
| US-20240382486-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885 |
| US-20160030428-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885 |
| US-20170281626-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885 |
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885 |
| US-20180311242-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885 |
| US-20200297726-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.